JPMorgan Chase & Co. Has $5.17 Million Position in Artivion, Inc. $AORT

Key Points

• JPMorgan Chase & Co. increased its stake in Artivion by 338.2% in Q3, buying an additional 94,312 shares to hold 122,199 shares worth $5.17 million (0.26% of the company), while institutional investors now own 86.37% of the stock.
• Insider selling was significant last quarter—insiders sold 133,043 shares worth about $4.98 million (including sales by John E. Davis and SVP Marshall S. Stanton), leaving insiders with a 7.60% ownership stake.
• Artivion beat the quarter (EPS $0.17 vs. $0.14 est.; revenue $118.3M, up 19.2% YoY), and analysts have an average rating of "Moderate Buy" with a $50.47 price target; the shares trade at a $1.64 billion market cap and a PE of 170.78.

JPMorgan Chase & Co. raised its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 338.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 122,199 shares of the company's stock after buying an additional 94,312 shares during the quarter. JPMorgan Chase & Co. owned 0.26% of Artivion worth $5,174,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Squarepoint Ops LLC purchased a new position in shares of Artivion during the 2nd quarter valued at $664,000. Kennedy Capital Management LLC raised its holdings in shares of Artivion by 20.8% during the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company's stock worth $11,437,000 after acquiring an additional 63,205 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Artivion during the second quarter valued at $3,750,000. Public Sector Pension Investment Board boosted its position in Artivion by 23.7% during the third quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company's stock valued at $6,858,000 after purchasing an additional 30,989 shares during the last quarter. Finally, Champlain Investment Partners LLC purchased a new position in Artivion in the third quarter valued at about $17,912,000. Hedge funds and other institutional investors own 86.37% of the company's stock.

Insider Buying and Selling

In other news, insider John E. Davis sold 4,573 shares of the firm's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $172,767.94. Following the sale, the insider directly owned 230,794 shares of the company's stock, valued at approximately $8,719,397.32. This trade represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Marshall S. Stanton sold 2,149 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $81,189.22. Following the transaction, the senior vice president directly owned 60,097 shares of the company's stock, valued at $2,270,464.66. This represents a 3.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 133,043 shares of company stock valued at $4,977,158 in the last quarter. Insiders own 7.60% of the company's stock.

Artivion Stock Performance

AORT opened at $34.15 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The company has a market cap of $1.64 billion, a PE ratio of 170.78 and a beta of 1.63. The stock has a 50-day moving average of $38.08 and a 200-day moving average of $41.95. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion's revenue was up 19.2% compared to the same quarter last year. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AORT. Canaccord Genuity Group dropped their target price on Artivion from $51.00 to $48.00 and set a "buy" rating on the stock in a research report on Friday, February 13th. Wall Street Zen cut Artivion from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Needham & Company LLC restated a "buy" rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Weiss Ratings upgraded shares of Artivion from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, February 20th. Finally, Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research report on Thursday, March 5th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $50.47.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.